Welcome to our dedicated page for Cytek Biosciences SEC filings (Ticker: CTKB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytek Biosciences, Inc. filings document the reporting, governance, and security structure of a Nasdaq-listed cell analysis solutions company. Its registered security is common stock traded under the CTKB symbol on the Nasdaq Global Select Market.
The company’s 8-K filings furnish financial-results releases, preliminary revenue updates, and related exhibit disclosures under Item 2.02. Proxy and annual meeting filings cover director elections, advisory executive compensation votes, auditor ratification, stockholder voting results, board-class matters, and other governance subjects. Together, these filings describe Cytek’s public-company reporting framework alongside its business in FSP instruments, reagents, software, services, and cell analysis technologies.
Cytek Biosciences reported modest 2025 revenue growth but a sharp drop in profitability and issued cautious 2026 guidance. Full-year 2025 revenue was $201.5 million, up 1% from 2024, with product revenue down and service revenue up.
GAAP gross margin fell to 52% from 55%, and operating expenses rose 10% to $144.8 million, driven mainly by higher general and administrative costs. The company posted a 2025 net loss of $66.5 million versus a $6.0 million loss in 2024, largely due to higher expenses and a non-cash deferred tax valuation allowance.
Adjusted EBITDA dropped to $5.0 million from $22.4 million, and cash and marketable securities declined to $261.5 million as of December 31, 2025, partly reflecting a $15.1 million share repurchase. For 2026, Cytek guides revenue to $205–$212 million, implying 2–5% growth.
Cytek Biosciences president and CEO Wenbin Jiang reported equity award activity involving restricted stock units and common shares. On February 18, 2026, 4,514 restricted stock units were converted into 4,514 shares of common stock at a price of 0.00 per share.
The Form 4 shows that 1,339 of these common shares, valued at 4.20 per share, were withheld and surrendered to Cytek Biosciences to cover tax withholding obligations tied to the vesting of this RSU award. After these transactions, Jiang directly held 5,359,827 shares of common stock.
Cytek Biosciences, Inc. director and Chief Technology Officer Yan Ming reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 18, 2026, 1,332 RSUs were converted into 1,332 shares of common stock at a stated price of $0.0000 per share.
On the same date, 395 shares of common stock at $4.20 per share were withheld and surrendered to Cytek to cover tax obligations arising from the RSU vesting, described as a tax-withholding disposition rather than an open-market sale. Following these transactions, Yan Ming directly held 6,074,264 common shares.
Cytek Biosciences, Inc. chief legal officer Valerie Barnett reported equity award activity involving restricted stock units and common shares. On February 18, 2026, 1,346 restricted stock units were exercised into 1,346 shares of common stock at a stated price of $0.00 per share.
On the same date, 525 common shares at $4.20 per share were withheld and surrendered to Cytek Biosciences to cover tax withholding obligations related to the vesting of this RSU award. After these transactions, Barnett directly held 116,462 shares of Cytek Biosciences common stock. The RSU award vests quarterly over four years, with an initial 4/48th tranche vesting on May 18, 2022, and 3/48th of the total shares vesting on each subsequent August 18, November 18, February 18, and May 18.
Cytek Biosciences, Inc. reported that it has issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company furnished this press release as Exhibit 99.1 to a current report, rather than treating it as formally filed financial information. The filing clarifies that the press release and related data are not incorporated into other securities law filings unless specifically referenced.
Cytek Biosciences (CTKB) chief technology officer and director reported multiple equity transactions on November 18, 2025 related to previously granted restricted stock units (RSUs). Several RSU tranches were converted into common stock, including blocks of 1,981, 7,363, 5,525 and 6,162 shares, reflecting ongoing vesting of long-term equity awards. To cover tax withholding from these vestings, a total of 4,? (aggregate of 483, 1,793, 1,346 and 1,501) shares were withheld and surrendered to the company at a price of $5.53 per share, rather than being sold on the open market. After these transactions, the insider directly beneficially owned 6,073,327 shares of Cytek common stock. The RSU grants continue to vest over multiple years on specified quarterly and annual dates.
Cytek Biosciences (CTKB) senior executive reports RSU vesting and share withholding transactions. On November 18, 2025, the SVP, Global Sales and Services converted multiple batches of restricted stock units (RSUs) into common stock and had shares withheld to cover taxes.
Form 4 data shows RSU exercises adding 1,536, 2,210, and 3,625 shares of common stock, with tax withholding sales of 393, 565, and 927 shares at $5.53 per share. After these transactions, the executive directly owned 28,902 shares of Cytek common stock.
The filing also reports remaining unvested or unsettled RSUs, with derivative holdings of 8,714, 20,628, and 48,338 RSUs, each tied to multi-year vesting schedules that allocate specific fractions of each award to vest on set dates in May, August, November, and March until fully vested.
Cytek Biosciences, Inc. insider activity: the company’s Chief Legal Officer reported multiple transactions on common stock tied to vesting of restricted stock units (RSUs) on November 18, 2025. Several RSU awards were converted into common shares, each RSU representing a right to receive one share of Cytek common stock.
On the same date, shares were also withheld and surrendered to Cytek to cover tax withholding obligations at a price of $5.53 per share. After these RSU conversions and tax withholdings, the reporting person directly beneficially owned 115,641 shares of Cytek common stock. The RSU awards vest over four-year schedules with quarterly and annual vesting dates as described in the filing.
Cytek Biosciences, Inc. (CTKB) reported insider equity activity by its Chief Financial Officer on 11/18/2025. The filing shows the vesting and settlement of restricted stock units (RSUs) into common stock, along with shares withheld to cover taxes. The CFO acquired 6,320 shares of common stock upon RSU vesting, then had 2,032 shares withheld and surrendered to the company at $5.53 per share for tax obligations. A second RSU vesting added 13,051 shares, followed by 4,196 shares withheld at the same price for taxes. After these transactions, the CFO directly owned 80,714 shares of common stock and continued to hold additional unvested RSUs, reflecting ongoing equity-based compensation rather than an open-market sale.
Cytek Biosciences (CTKB) president and CEO, who also serves as a director, reported several equity transactions on November 18, 2025 related to restricted stock units (RSUs). Multiple RSU awards were converted into common stock, with 6,758, 11,781, 22,100 and 29,002 shares of common stock issued as each RSU grant vested.
To cover tax withholding from these vestings, the issuer withheld and received back 2,660, 4,636, 8,697 and 11,413 shares at a price of $5.53 per share. After the reported transactions, the executive beneficially owned 5,356,652 shares of Cytek common stock directly, and continued to hold RSU awards covering 4,514, 62,837, 206,273 and 386,699 units that will vest over multiple years on specified quarterly and annual dates.